News >

Fluoride PET/CT Scan Could Guide Treatment Selection in Bone Metastatic CRPC

Published: Friday, Jun 26, 2015

Dr. Elba C. Etchebehere

Elba C. Etchebehere, MD, PhD

Bone marrow failure (BMF) may occur following treatment with radium-223 (Xofigo) in a portion of patients with metastatic castration-resistant prostate cancer (CRPC) who have high skeletal tumor burden, according to a study presented at the 2015 ASCO Annual Meeting by Elba C. Etchebehere, MD, PhD.1 The findings suggest that whole-body 18F sodium fluoride PET/CT (Fluoride PET/CT) could be used as an imaging biomarker for selecting the best candidates for treatment with radium-223.

  1. Etchebehere EC, Araujo JC, Milton D, et al. Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone marrow failure after radium-223. J Clin Oncol. 2015;33 (suppl; abstr 11012).
  2. Etchebehere E, Araujo JC, Fox PS, et al. Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival. J Nucl Med. 2015 Jun 11. pii: jnumed.115.158626. [Epub ahead of print]

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication